Feasibility and preliminary effects of high-intensity interval training vs. moderate-intensity continuous training on inflammatory and metabolic biomarkers in type 2 diabetes: a pilot randomized controlled trial
- 10 October 2025
- journal article
- research article
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 24 (2) , 1-12
Abstract
Background Elevated plasma calprotectin, an inflammatory biomarker, is linked to higher cardiovascular risk in type 2 diabetes (T2DM), suggesting lifestyle interventions like exercise may help regulate it. This pilot study evaluated the feasibility of future full-scale trial for comparing the effect of high-intensity interval training (HIIT) vs. moderate-intensity continuous training (MICT) on calprotectin in T2DM patients without cardiovascular disease. Methods This open-label, randomized controlled pilot trial was conducted from December 2018 to March 2019 at the Rajaie Cardiovascular Institute, Tehran, Iran. Participants over 18 years of age with T2DM, an HbA1c between 6.5% and 10%, a BMI between 24 and 35 kg/m2, and stable medication use for at least four weeks before enrollment, were randomly assigned at a 1:1 ratio to HIIT or MICT group for eight weeks. Primary endpoints included recruitment and retention rates, whereas changes in biomarkers after training were secondary endpoints. Results Out of 58 T2DM patients assessed for eligibility, 18 were recruited (9 females, 9 males; mean age: 52 ± 6.0 years; mean BMI: 28.7 ± 3.8 kg/m2), resulting in a recruitment rate of 32%. All participants completed the study, and no adverse events occurred. The calprotectin level decreased in the HIIT group but increased in the MICT group [mean difference (CI95%): 73.4(−337.1, 483.9) vs. −15.4(−553.9, 523.2)]. Conclusions This study demonstrated efficient participant recruitment, complete retention, and safety, indicating that a full-scale trial is feasible. The reduction in calprotectin levels in the HIIT group supports further investigation in the full-scale trial. Trial registration Iranian Registry of Clinical Trials (IRCT), IRCT20181129041797N1, Registered 25 Dec 2018, https://irct.behdasht.gov.ir/trial/35598Keywords
This publication has 43 references indexed in Scilit:
- Role of calprotectin in cardiometabolic diseasesCytokine & Growth Factor Reviews, 2014
- Calprotectin in Rheumatoid ArthritisMolecular Diagnosis & Therapy, 2013
- Increased Levels of Calprotectin in Obesity Are Related to Macrophage Content: Impact on Inflammation and Effect of Weight LossMolecular Medicine, 2011
- What is a pilot or feasibility study? A review of current practice and editorial policyBMC Medical Research Methodology, 2010
- Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Theraphy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trialAmerican Heart Journal, 2008
- Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel diseaseInflammatory Bowel Diseases, 2006
- Platelet Expression Profiling and Clinical Validation of Myeloid-Related Protein-14 as a Novel Determinant of Cardiovascular EventsCirculation, 2006
- Circulating markers of inflammation and atherosclerosisAtherosclerosis, 2003
- Preventing Macrovascular Disease in Patients with Type 2 Diabetes MellitusAmerican Journal of Cardiovascular Drugs, 2003
- Maximal oxygen intake and nomographic assessment of functional aerobic impairment in cardiovascular diseaseAmerican Heart Journal, 1973